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Increased fetuin-A levels following
treatment with a vitamin D analog
To the Editor: Fetuin-A is one of the several potential
vascular calciﬁcation inhibitors in chronic kidney disease
(CKD) patients; it seems to protect from precipitation of
calcium phosphate under extra-osseous calciﬁcation stress by
organizing a fetuin–mineral complex (FMC).1
Vitamin D has been demonstrated to promote ectopic
calciﬁcations by different mechanisms that also include
fetuin-A exhaustion as a result of FMC formation. This
hypothesis was supported by in vivo evidence in rats fed
with toxic doses of vitamin D,2 which induced ectopic
calciﬁcations and reduction of circulating fetuin-A; however,
this mechanism has never been investigated in humans.
In addition, Matsui et al.1 recently reported a slight decrease
in serum fetuin-A levels and a marked rise in FMC in uremic
rats with very high levels of calcium phosphorus (Ca P)
product.
We studied fetuin-A serum level variations in hemodialysis
patients suffering from secondary hyperparathyroidism,
before and after the administration of a vitamin D analog
(paricalcitol).
We treated 10 consecutive hemodialysis patients with
hyperparathyroidism, who had never received vitamin D
treatment, with i.v. paricalcitol 5mg thrice weekly; we
obtained their sera before the ﬁrst paricalcitol administration
(t0), and after 1 week (t1), 4 weeks (t4), and 8 weeks (t8);
serum levels of fetuin-A (measured using a human fetuin-A
ELISA kit, Epitope Diagnostics, San Diego, CA), high-
sensitivity C-reactive protein (hsCRP), total intact parathy-
roid hormone (PTH), and serum calcium and phosphorus
levels were measured. The results are shown in Figure 1.
Contrary to that reported in rats, we observed, comparing t8
with t0, a progressive and statistically signiﬁcant increase in
serum fetuin-A levels (P¼ 0.01); there was also an increase in
the Ca P product (P¼ 0.42) and a decrease in PTH (P¼ 0.07)
and hsCRP levels (P¼ 0.06), but these changes were not
statistically signiﬁcant. Because it is well known that inﬂamma-
tion, as assessed by hsCRP, may condition fetuin-A synthesis,
we investigated whether changes in fetuin-A correlated with
changes in hsCRP; in our patients there was no signiﬁcant
correlation between these two parameters (r¼0.188,
P¼ 0.60); therefore, the increase in fetuin-A we observed after
paricalcitol treatment did not seem to be accounted for by
changes in the inﬂammatory status of our patients.
The increase in fetuin-A serum levels could be due to
hepatic stimulation of fetuin-A synthesis induced by vitamin
D through its action on the hepatocyte vitamin D receptor.
In agreement with our data, serum levels of 1–25 OH
dihydroxy-vitamin D in untreated CKD patients were found
to correlate with serum fetuin-A levels.3
In conclusion, although vitamin D may elicit vascular
calciﬁcation through an increase in the Ca P product, in
humans it is apparent that it may also activate a counter-
regulatory mechanism that leads to an increased production
of fetuin-A. These data lend further support to the view that
vitamin D may exert pleiotropic effects on different organ
systems, as reviewed by Verstuyf et al.4 in a recent issue of
Kidney International.
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The Author Replies: Manenti et al.1 observed a signiﬁcant
increase in serum fetuin-A levels starting a few weeks after
thrice-a-week paracalcitol treatment of 10 patients on chronic
hemodialysis. The simple consequence could be that such
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Figure 1 | Serum levels of fetuin-A, CaP product,
parathyroid hormone (PTH), and high-sensitivity C-reactive
protein (hsCRP) in the 10 patients studied, before (t0) and
after 1 week (t1), 4 weeks (t4), and 8 weeks (t8) of paricalcitol
treatment.
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